Sponsor of the Day:
Jerkmate
https://www.prnewswire.com/news-releases/neurocrine-to-acquire-soleno-therapeutics-expanding-its-endocrinology-and-rare-disease-portfolio-302734531.html
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Apr 6, 2026 - VYKAT™ XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy...
soleno therapeuticsrare diseaseneurocrineacquireexpanding
https://www.europapress.es/economia/noticia-neurocrine-comprara-soleno-2516-millones-20260406165426.html
Neurocrine comprará Soleno por 2.516 millones
Apr 6, 2026 - Neurocrine Biosciences ha llegado a un acuerdo para adquirir Soleno Therapeutics a cambio de 2.900...
por 2neurocrinesoleno516millones
https://www.biospace.com/deals/neurocrine-nabs-rare-obesity-disorder-drug-in-surprising-2-9b-soleno-deal
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal - BioSpace
Apr 6, 2026 - While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to...
2 9bneurocrinenabsrareobesity
https://www.fool.com/investing/breakfast-news/2026/04/06/breakfast-news-soleno-soars-30-on-buyout-talk/
Breakfast News: Soleno Soars 30% On Buyout Talk | The Motley Fool
Apr 6, 2026 - Neurocrine's reported biotech buy, Coinbase's new regulatory approval, and more...
breakfast newsmotley foolsolenosoars30
https://www.statnews.com/2026/04/06/neurocrine-biosciences-soleno-therapeutics-acquisition-prader-willi-vykat/
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal
Apr 6, 2026 - As part of the deal, Neurocrine will pick up an approved drug for the rare disease Prader-Willi syndrome, which has seen a successful launch.
neurocrine biosciencessoleno therapeutics2 9bbuydeal
https://soleno.life/
Soleno Therapeutics – Development and commercialization of novel therapeutics for the treatment of...
soleno therapeuticsdevelopmentcommercializationnoveltreatment
https://www.financialcontent.com/quote/NQ:SLNO
Soleno Therapeutics, Inc. - Common Stock (SLNO) Stock Price, News, Quote & History |...
The current price of Soleno Therapeutics, Inc. - Common Stock (SLNO) is 52.48 — it has gone up by +0.13 (0.25%) today. Soleno Therapeutics Inc is a...
therapeutics inc commonprice news quotesolenostockhistory